CVS Health Corp. stock (US1266501006): Glenview trims stake after 80% run as Q1 2026 earnings beat lifts outlook

After a strong 80% total return since 2024, hedge fund Glenview Capital has partially cashed in its CVS Health position shortly after the healthcare group beat Q1 2026 earnings expectations and raised full-year guidance. What this means for the stock and US investors.

CVS Health Corp. has moved back into the spotlight after hedge fund Glenview Capital reported on May 21, 2026 that its concentrated investment in the US healthcare group has generated an 80% total return since purchases began in May 2024, and that it has recently rebalanced the position following strong first-quarter results and higher full-year guidance, according to Stock Titan as of 05/21/2026 and GuruFocus as of 05/21/2026.

In parallel, CVS Health beat Wall Street expectations with first-quarter 2026 earnings per share of 2.57 USD versus a 2.21 USD consensus and delivered what S&P Global Ratings called “solid results,” supported by last-12-month adjusted debt to EBITDA of 3.8x, according to MarketBeat as of 05/06/2026 and S&P Global Ratings as of 05/12/2026.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: CVS Health Corp.
• Sector/industry: Healthcare, pharmacy and managed care
• Headquarters/country: Woonsocket, Rhode Island, United States
• Core markets: United States retail pharmacy, pharmacy benefit management, health insurance
• Key revenue drivers: Retail pharmacy sales, insurance premiums, pharmacy benefit management services
• Home exchange/listing venue: New York Stock Exchange (ticker: CVS)
• Trading currency: USD

CVS Health Corp.: core business model

CVS Health Corp. operates as a diversified healthcare company built around three main pillars: retail pharmacy locations, a large pharmacy benefit management unit and a health insurance and managed care business. These segments are closely integrated, giving the group a broad presence across the US healthcare value chain.

The company runs one of the largest pharmacy chains in the United States, combining prescription dispensing with over-the-counter products and basic health services. In parallel, its pharmacy benefit management arm negotiates prices and manages drug benefits for employers, insurers and government programs, while its insurance subsidiary offers health plans across commercial, Medicare and Medicaid lines.

This integrated setup aims to steer patients through the healthcare system more efficiently, leveraging data from pharmacies, insurance claims and benefit management to coordinate care and control costs. The strategy has positioned CVS Health as a central player for US healthcare spending, with relevance for investors focused on the long-term evolution of the American health system.

Main revenue and product drivers for CVS Health Corp.

The retail pharmacy network is a visible anchor of CVS Health’s business model and remains a key revenue driver. Stores generate income from filling prescriptions, selling generics and branded drugs, and providing front-of-store merchandise such as health, wellness and personal care products. Prescription volumes and reimbursement levels from payers are critical factors for this segment’s performance.

The pharmacy benefit management unit contributes substantial fee and spread-based revenue through managing drug plans, processing prescriptions and negotiating discounts with manufacturers. Its earnings depend on scale, the ability to secure competitive pricing and the capacity to keep medical and pharmacy cost trends under control for clients, which include large employers and health plans across the US.

CVS Health’s managed care and insurance segment generates premium revenue from members enrolled in a variety of plans, particularly Medicare Advantage, Medicaid managed care and employer-sponsored coverage. Growth in membership, risk adjustment payments and medical cost management all influence profitability. The segment also interacts with government policy, since reimbursement levels and regulatory frameworks shape margins across the US health insurance market.

Q1 2026 earnings beat and raised guidance

In early May 2026, CVS Health reported its financial results for the first quarter of 2026 and exceeded analyst expectations on earnings per share. The company delivered EPS of 2.57 USD, ahead of the 2.21 USD consensus estimate collected by MarketBeat, according to MarketBeat as of 05/06/2026. The beat reflected contributions from across its businesses, including continued momentum in health insurance and cost management efforts.

S&P Global Ratings described CVS Health’s first-quarter 2026 performance as “solid” and pointed to last-12-month adjusted debt to EBITDA of 3.8x, indicating ongoing deleveraging compared with levels reached after previous acquisitions, according to S&P Global Ratings as of 05/12/2026. The agency’s commentary underscored that earnings and cash flow generation support a gradual strengthening of the balance sheet.

Following the first-quarter results, Glenview Capital noted that CVS Health raised its annual guidance for 2026, reflecting management’s confidence in the trajectory of the business, according to Stock Titan as of 05/21/2026. While exact guidance figures were not detailed in Glenview’s statement, the hedge fund highlighted that the updated outlook followed a quarter that it described as healthy.

MarketBeat data also indicate that CVS Health has not yet confirmed the date of its next earnings release, but based on historical patterns, the estimated next earnings report could fall around late July 2026, according to MarketBeat as of 05/06/2026. For investors, this time frame may serve as the next major catalyst to reassess the company’s progress and the sustainability of its guidance.

Glenview Capital’s 80% return and position rebalance

Against the backdrop of these earnings dynamics, Glenview Capital Management, a hedge fund known for concentrated positions in healthcare and other sectors, publicly commented on its CVS Health investment in a press release dated May 21, 2026. The firm stated that it established a concentrated position in CVS shares in May 2024 and has since achieved a total return of 80% on those purchases, according to Stock Titan as of 05/21/2026.

Glenview attributed this performance to what it described as a “long-term cultural and operational turnaround” at CVS Health, emphasizing changes in the company’s approach and execution. The fund noted that after the strong run in the stock and the Q1 2026 results, it rebalanced its position in May 2026 by selling 3.75 million shares, while keeping CVS Health as one of its three largest holdings, according to the same press release.

GuruFocus reported similar details and pointed to CVS Health’s market capitalization of about 119.07 billion USD and a proprietary GF Score of 80 out of 100, which the platform associates with potential for long-term returns, according to GuruFocus as of 05/21/2026. Glenview’s decision to trim rather than exit the position signals, in the fund’s view, continued conviction in the company’s near-, medium- and long-term prospects despite realizing some gains.

The hedge fund also highlighted that CVS Health had increased its annual guidance after reporting healthy first-quarter numbers, reinforcing its thesis that the operational changes underway are translating into financial performance, according to Stock Titan as of 05/21/2026. For US investors following institutional activity, this combination of partial profit-taking and continued large exposure provides an insight into how one professional investor balances risk and opportunity after a substantial share price move.

Operational and cultural transformation at CVS Health

Both Glenview Capital and GuruFocus pointed to an ongoing operational and cultural transformation at CVS Health as a key driver of performance. While specific internal initiatives were not detailed, the comments suggest changes in how the company manages its integrated businesses, focuses on efficiency and positions itself in a competitive US healthcare market, according to GuruFocus as of 05/21/2026.

In many diversified healthcare groups, such transformations often involve streamlining overlapping operations, investing in technology and data analytics, and updating organizational culture to respond more quickly to regulatory and market changes. CVS Health has previously emphasized the importance of connecting pharmacy, benefits and insurance data to improve patient outcomes and control costs, and any progress in these areas can have meaningful effects on both quality of care and financial results in the US health system.

The company’s participation in Medicaid managed care and other government-related programs also figures into this transformation. Research from the Georgetown University Center for Children and Families noted that CVS Health was among the “Big Five” Medicaid managed care organizations reporting financial and enrollment results for the first quarter of 2026, highlighting the significance of this market segment for large US payers, according to Georgetown CCF as of 05/21/2026.

At the community level, CVS Health has also reported on its broader economic and social footprint. In a 2024-focused release, the company stated that its operations generated an estimated 12.5 billion USD in economic impact in New Jersey and supported more than 39,000 jobs in the state in fiscal year 2024, according to CVS Health as of 04/23/2025. Although this information relates to a prior period, it illustrates the scale at which the company engages with local economies across the US.

Why CVS Health Corp. matters for US investors

For US investors, CVS Health’s relevance stems from its role at the intersection of retail pharmacy, health insurance and pharmacy benefit management. The company’s NYSE listing under the ticker CVS provides exposure to multiple parts of the US healthcare system in a single stock, which can behave differently from pure-play insurers or standalone pharmacy chains during regulatory or market shifts.

Policy decisions around Medicare, Medicaid and drug pricing can have a direct impact on CVS Health’s earnings and cash flows. Legislators and regulators regularly review reimbursement levels, pharmacy benefit management practices and competition in the health insurance market. As a result, CVS Health shares often react to news related to healthcare reform, prescription drug policy and government program funding in the United States.

The scale of CVS Health’s insurance and Medicaid managed care operations also makes it a key player in discussions about access and affordability in US healthcare. Enrollment trends in government programs, the evolution of value-based care models and competitive dynamics among the “Big Five” managed care organizations all influence the company’s growth trajectory and long-term strategic positioning, according to Georgetown CCF as of 05/21/2026.

Additionally, CVS Health’s presence in communities through its pharmacies and clinics means that demographic changes, consumer preferences and shifts toward digital health can shape both its revenue mix and investment needs. US investors monitoring structural trends such as aging populations, chronic disease prevalence and telehealth adoption often consider companies like CVS Health as important indicators of how the broader healthcare ecosystem is adapting.

Conclusion

CVS Health Corp. has recently combined an earnings beat in the first quarter of 2026 with a raised full-year outlook and continued deleveraging, which together underpin its role as a diversified US healthcare group. Glenview Capital’s disclosure of an 80% total return since 2024 and its decision to trim but maintain a top-three position highlight how at least one institutional investor views the balance between gains realized and potential ahead. At the same time, regulatory exposure, execution on operational changes and competition across pharmacy, benefits and insurance remain central factors that US investors should weigh when assessing the company’s future trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.